Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: Invest Ophthalmol Vis Sci. 2008 Jun 19;49(10):4392–4398. doi: 10.1167/iovs.08-1830

Figure 3.

Figure 3

Effect of a caspase 1 inhibitor on LPS-induced inhibition of lacrimal gland secretion. Lightly anesthetized female BALB/c mice received subcutaneous injections (100 μL) of vehicle (DMSO+PEG400) or Z-YVAD-FMK (0.1 mg). Twenty-four hours later, the mice received second subcutaneous injections of Z-YVAD-FMK (or vehicle) followed by injection (2 μL) of LPS (25 μg) or saline (vehicle for LPS) into the exorbital lacrimal glands. Twenty-four hours later, lacrimal glands were removed and lobules were prepared to measure protein secretion. Data are the mean ± SEM from three independent experiments. *Statistically significant difference from spontaneous secretion. #Statistically significant difference from LPS + vehicle.